Moreover, increased expression levels of PRMT1 are significantly correlated with unfavorable prognosis in HCC patients, indicating its potential as a predictive biomarker for treatment efficacy and survival outcomes [145]. Here, PRMT1 is linked to hepatocellular carcinoma.